Financial News Feed

No summary available....

Read more

No summary available....

Read more

95 Biggest Movers From Yesterday
05:01am, Thursday, 09'th May 2019
Gainers Corindus Vascular Robotics, Inc. (NYSE: CVRS) climbed 35.71 percent to close at $2.85 on Wednesday following Q1 results. Akorn, Inc. (NASDAQ: AKRX) …...

Read more

Akorn (AKRX) Q1 2019 Earnings Call Transcript
01:24pm, Wednesday, 08'th May 2019
AKRX earnings call for the period ending March 31, 2019....

Read more

Akorn beats Q1 consensus
11:50am, Tuesday, 07'th May 2019
No summary available....

Read more

Akorn beats by $0.07, beats on revenue
11:11am, Tuesday, 07'th May 2019
No summary available....

Read more

Akorn Q1 2019 Earnings Preview
09:30pm, Monday, 06'th May 2019
Akorn (NASDAQ:AKRX) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS Estimate is -$0.17 and the cons...

Read more

No summary available....

Read more

Shares of specialty generic pharma company Akorn, Inc. (NASDAQ: AKRX ) are advancing solidly Monday morning thanks to twin announcements announced late last week. What Happened Akorn said the FDA greenlighted two of its generic candidates: 1) fluticasone propionate nasal spray USP, 50 mcg per spray and 2) loteprednol etabonate ophthalmic suspension, 0.5 percent. The fluticasone propionate nasal spray, indicated as a temporary relief for … Full story available on Benzinga.com...

Read more

No summary available....

Read more

Gainers: [[AKRX]] +14.4%. [[ATAI]] +4.9%. [[EXPO]] +4.5%. [[PYX]] +3.7%. [[SGH]] +3.2%. Losers: [[ISRG]] -7.2%. [[MT]] -6.2%. [[MBIO]] -3.7%. [[AVYA]] -2.7...

Read more

No summary available....

Read more

LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ: AKRX ), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn's President and Chief Executive Officer, stated, "We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Among other private label possibilities, we have a supply agreement in place for Fluticare® through Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV)." Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older. Fluticare® is a registered trademark of Innovus Pharmaceuticals, Inc. About Akorn Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals....

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank